Uncovering the metabolomic fingerprint of breast cancer

Catherine Oakman, Leonardo Tenori, Laura Biganzoli, Libero Santarpia, Silvia Cappadona, Claudio Luchinat, Angelo Di Leo

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Metabolomics, the study of metabolites and small intermediate molecules, may play a key role in further elucidation of breast cancer. This dynamic, simultaneous assessment of thousands of metabolites allows identification of the presence, concentration and fluxes of specific metabolites, and recognition of the critical metabolic pathways recruited in carcinogenesis. Studies of tumour cell and tissue allow focused analysis on the tumour, whilst studies of biofluids have the appeal of concurrent assessment of tumour and host. Elucidation of these metabolites and pathways may provide essential insights into both the intercellular environment and host/tumour interaction, allowing recognition of new biomarkers for diagnosis and prediction of outcome, new therapy targets and novel approaches for monitoring response and toxicity. Certainly, the field of metabolomics may evolve as a valuable, complementary clinical tool. In this review, current metabolomic data in breast cancer will be presented. The dominant metabolic pathways and metabolite disturbances associated with malignant transformation of breast cells will be outlined, leading to an overview of potential clinical implications for individuals with breast cancer.

Original languageEnglish
Pages (from-to)1010-1020
Number of pages11
JournalInternational Journal of Biochemistry and Cell Biology
Volume43
Issue number7
DOIs
Publication statusPublished - Jul 2011

Fingerprint

Metabolomics
Dermatoglyphics
Metabolites
Breast Neoplasms
Tumors
Metabolic Networks and Pathways
Neoplasms
Critical Pathways
Biomarkers
Carcinogenesis
Breast
Toxicity
Cells
Tissue
Fluxes
Molecules
Monitoring
Therapeutics

Keywords

  • Breast cancer
  • Carcinogenesis
  • Metabolic
  • Metabolomic
  • Pathways

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Cite this

Uncovering the metabolomic fingerprint of breast cancer. / Oakman, Catherine; Tenori, Leonardo; Biganzoli, Laura; Santarpia, Libero; Cappadona, Silvia; Luchinat, Claudio; Di Leo, Angelo.

In: International Journal of Biochemistry and Cell Biology, Vol. 43, No. 7, 07.2011, p. 1010-1020.

Research output: Contribution to journalArticle

Oakman, C, Tenori, L, Biganzoli, L, Santarpia, L, Cappadona, S, Luchinat, C & Di Leo, A 2011, 'Uncovering the metabolomic fingerprint of breast cancer', International Journal of Biochemistry and Cell Biology, vol. 43, no. 7, pp. 1010-1020. https://doi.org/10.1016/j.biocel.2010.05.001
Oakman, Catherine ; Tenori, Leonardo ; Biganzoli, Laura ; Santarpia, Libero ; Cappadona, Silvia ; Luchinat, Claudio ; Di Leo, Angelo. / Uncovering the metabolomic fingerprint of breast cancer. In: International Journal of Biochemistry and Cell Biology. 2011 ; Vol. 43, No. 7. pp. 1010-1020.
@article{fb0d3851cfba4ca9af1a9adb3c6a28cc,
title = "Uncovering the metabolomic fingerprint of breast cancer",
abstract = "Metabolomics, the study of metabolites and small intermediate molecules, may play a key role in further elucidation of breast cancer. This dynamic, simultaneous assessment of thousands of metabolites allows identification of the presence, concentration and fluxes of specific metabolites, and recognition of the critical metabolic pathways recruited in carcinogenesis. Studies of tumour cell and tissue allow focused analysis on the tumour, whilst studies of biofluids have the appeal of concurrent assessment of tumour and host. Elucidation of these metabolites and pathways may provide essential insights into both the intercellular environment and host/tumour interaction, allowing recognition of new biomarkers for diagnosis and prediction of outcome, new therapy targets and novel approaches for monitoring response and toxicity. Certainly, the field of metabolomics may evolve as a valuable, complementary clinical tool. In this review, current metabolomic data in breast cancer will be presented. The dominant metabolic pathways and metabolite disturbances associated with malignant transformation of breast cells will be outlined, leading to an overview of potential clinical implications for individuals with breast cancer.",
keywords = "Breast cancer, Carcinogenesis, Metabolic, Metabolomic, Pathways",
author = "Catherine Oakman and Leonardo Tenori and Laura Biganzoli and Libero Santarpia and Silvia Cappadona and Claudio Luchinat and {Di Leo}, Angelo",
year = "2011",
month = "7",
doi = "10.1016/j.biocel.2010.05.001",
language = "English",
volume = "43",
pages = "1010--1020",
journal = "International Journal of Biochemistry and Cell Biology",
issn = "1357-2725",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - Uncovering the metabolomic fingerprint of breast cancer

AU - Oakman, Catherine

AU - Tenori, Leonardo

AU - Biganzoli, Laura

AU - Santarpia, Libero

AU - Cappadona, Silvia

AU - Luchinat, Claudio

AU - Di Leo, Angelo

PY - 2011/7

Y1 - 2011/7

N2 - Metabolomics, the study of metabolites and small intermediate molecules, may play a key role in further elucidation of breast cancer. This dynamic, simultaneous assessment of thousands of metabolites allows identification of the presence, concentration and fluxes of specific metabolites, and recognition of the critical metabolic pathways recruited in carcinogenesis. Studies of tumour cell and tissue allow focused analysis on the tumour, whilst studies of biofluids have the appeal of concurrent assessment of tumour and host. Elucidation of these metabolites and pathways may provide essential insights into both the intercellular environment and host/tumour interaction, allowing recognition of new biomarkers for diagnosis and prediction of outcome, new therapy targets and novel approaches for monitoring response and toxicity. Certainly, the field of metabolomics may evolve as a valuable, complementary clinical tool. In this review, current metabolomic data in breast cancer will be presented. The dominant metabolic pathways and metabolite disturbances associated with malignant transformation of breast cells will be outlined, leading to an overview of potential clinical implications for individuals with breast cancer.

AB - Metabolomics, the study of metabolites and small intermediate molecules, may play a key role in further elucidation of breast cancer. This dynamic, simultaneous assessment of thousands of metabolites allows identification of the presence, concentration and fluxes of specific metabolites, and recognition of the critical metabolic pathways recruited in carcinogenesis. Studies of tumour cell and tissue allow focused analysis on the tumour, whilst studies of biofluids have the appeal of concurrent assessment of tumour and host. Elucidation of these metabolites and pathways may provide essential insights into both the intercellular environment and host/tumour interaction, allowing recognition of new biomarkers for diagnosis and prediction of outcome, new therapy targets and novel approaches for monitoring response and toxicity. Certainly, the field of metabolomics may evolve as a valuable, complementary clinical tool. In this review, current metabolomic data in breast cancer will be presented. The dominant metabolic pathways and metabolite disturbances associated with malignant transformation of breast cells will be outlined, leading to an overview of potential clinical implications for individuals with breast cancer.

KW - Breast cancer

KW - Carcinogenesis

KW - Metabolic

KW - Metabolomic

KW - Pathways

UR - http://www.scopus.com/inward/record.url?scp=79958179526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958179526&partnerID=8YFLogxK

U2 - 10.1016/j.biocel.2010.05.001

DO - 10.1016/j.biocel.2010.05.001

M3 - Article

C2 - 20460168

AN - SCOPUS:79958179526

VL - 43

SP - 1010

EP - 1020

JO - International Journal of Biochemistry and Cell Biology

JF - International Journal of Biochemistry and Cell Biology

SN - 1357-2725

IS - 7

ER -